Fulgent Genetics (FLGT) Piper Sandler 36th Annual Healthcare Conference summary

Business overview and structure

• Operations are divided into laboratory services and drug development, with lab services as the main revenue driver.

• Laboratory services include precision diagnostics (NGS-based), anatomic pathology, and biopharma services.

• Precision diagnostics cover reproductive health, rare diseases, oncology, and adult genetics.

• Biopharma services offer lab capabilities to pharma partners, including spatial biology and proteomics.

• Drug development leverages a nano-delivery platform for new and reformulated drugs, with a focus on oncology.

Financial performance and guidance

• 2024 revenue guidance is $280 million, with $170–171 million from precision diagnostics and $95–96 million from anatomic pathology.

• Biopharma services contribute the remaining revenue.

• Gross margins improved from 28–29% to around 40% over the past six to seven quarters.

• Targeting gross margins at or above 40% for 2025 and 2026.

• Cash position is strong at $800 million, supporting acquisitions and investments.

Technology and operational differentiation

• Proprietary technology platform enables efficient sample processing, custom bioinformatics, and rapid turnaround times.

• Average turnaround for carrier screening is 12 days, significantly faster than competitors.

• Large test menu (20,000+ tests) maintained efficiently due to unified workflows and technology.

• Specialized sales teams target distinct market segments, supporting commercial focus.